Previous Steps To Access

2019

25th November:
FDA GRANTS PRIORITY REVIEW TO RISDIPLAM FOR THE TREATMENT OF SMA


2018

17th December: 
ROCHE'S RISDIPLAM GRANTED PRIME DESIGNATION BY EMA


2017

17th January: 
ROCHE DRUG RG7916 GRANTED ORPHAN DRUG STATUS IN THE US